<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040947</identifier>
<setSpec>1137-2273</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Manopause and cardiovascular risk</dc:title>
<dc:description xml:lang="en">In Spain, menopausal woman is threatened    by the some cardiovascular risk factors that affect    to male population with the same age.    Their cardiovascular mortality is minor that    those male, but we must no neglect woman    with cardiovascular risk factors. Replacement    hormonal therapy has not any role on primary    or secondary cardiovascular prevention in postmenopausal    women. But diabetic woman is a    group with high cardiovascular risk, and intensive    therapy will be considered as great utility    in primary prevention. In female patients with    coronary or cerebrovascular developed disease    these therapies have the same rentability that    in male patients, so we will must no make differences    about therapeutic guidelines</dc:description>
<dc:creator>Baos Vicente, V</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La mujer posmenopáusica en España se ve    amenazada en el sentido cardiovascular con los    mismos factores de riesgo que afectan a la población    masculina de la misma edad. Su mortalidad    cardiovascular es menor que el varón, pero    no por ello debemos descuidar la atención a    la mujer que presente estos factores de riesgo o    ya haya manifestado síntomas de enfermedad    cardiovascular. La Terapia Hormonal Sustitutiva    no tiene, en la actualidd ningún papel en la    prevención primaria o secundaria de la patología    cardiovascular de la mujer posmenopáusica.    La mujer diabética es un grupo de alto riesgo    cardiovascular dentro de las mujeres posmenopáusicas.    La terapia intensiva (antihipertensiva,    hipolipemiantes) será de gran utilidad en    prevención primaria. En aquellas pacientes que    hayan desarrollado la enfermedad coronaria o    cerebrovascular, las terapias indicadas tienen    el mismo grado de rentabilidad que en los varones,    por lo que no se deberán hacer diferencias    de abordaje terapéutico</dc:description>
<dc:source>Cienc. ginecol;9(5): 285-293, sept.-oct. 2005. ilus</dc:source>
<dc:identifier>ibc-040947</dc:identifier>
<dc:title xml:lang="es">Menopausia y riesgo cardiovascular</dc:title>
<dc:subject>^d28632</dc:subject>
<dc:subject>^d33862^s28898</dc:subject>
<dc:subject>^d3942^s22080</dc:subject>
<dc:subject>^d5059</dc:subject>
<dc:subject>^d33862^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2359^s22044</dc:subject>
<dc:subject>^d2359^s22012</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d3439^s22048</dc:subject>
<dc:subject>^d2359^s22027</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d2359^s22080</dc:subject>
<dc:subject>^d2359^s22053</dc:subject>
<dc:subject>^d3439^s22074</dc:subject>
<dc:subject>^d3942^s22012</dc:subject>
<dc:subject>^d5059^s22000</dc:subject>
<dc:subject>^d3942^s22044</dc:subject>
<dc:subject>^d22243^s22031</dc:subject>
<dc:subject>^d3942^s22027</dc:subject>
<dc:subject>^d5059^s22063</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
